Results 81 to 90 of about 3,831 (231)
Activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates in Iran [PDF]
, 2022 We evaluated the activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates.
Nikkhahi, Farhad +16 more
core +1 more source
Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]
Drugs, 2018 The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials. Intravenous meropenem/vaborbactam (Vabomere™) is the first carbapenem/β-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis ...
openaire +2 more sources
Bocillin™ competition assay probing inhibition of P. aeruginosa PBP3 by vaborbactam.
, 2021 SDS PAGE gel fluorescence scan of PBP3 reacted with the fluorescent BocillinTM reporter β-lactam in the presence of varying concentrations of the vaborbactam inhibitor.
Vijay Kumar (377076) +5 more
core +1 more source
Infectious Diseases and Therapy, 2018 Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink +22 more
doaj +1 more source
Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics
MicrobiologyOpen, Volume 15, Issue 1, February 2026.Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li +4 more
wiley +1 more source
, 2018 Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE ...
John P Mills +3 more
core +1 more source
Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.Background Carbapenem‐resistant Klebsiella pneumoniae (CRKP) has become a global public health threat, with significantly increased morbidity and mortality among high‐risk inpatients. High‐risk genotypes of CRKP, primarily including K. pneumoniae carbapenemase (KPC), oxacillinase‐48–like (OXA‐48–like), New Delhi metallo‐β‐lactamase (NDM), imipenemase ...
Qiongfang Zhang +5 more
wiley +1 more source
Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy
Pharmaceutics, 2023 Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria.
Beatriz Fernández-Rubio +9 more
doaj +1 more source
Antibiotics, 2022 Objectives: The aim of this study was to describe our experience of a combination treatment including meropenem/vaborbactam (M/V) plus aztreonam (ATM) for bloodstream infections (BSIs) due to ceftazidime/avibactam-resistant Klebsiella pneumoniae (CAZ/AVI-
Alessandra Belati +5 more
doaj +1 more source
International Journal of Microbiology, Volume 2026, Issue 1, 2026.Carbapenem‐resistant Klebsiella pneumoniae poses a significant public health threat due to limited therapeutic options. This study investigated the potential of xylitol, a sugar alcohol, to enhance meropenem activity and combat biofilms in a clinical carbapenem‐resistant K. pneumoniae strain (Kp5) and a standard susceptible strain (K. pneumoniae subsp.
Omid Ahlelyorof +5 more
wiley +1 more source